Multisite Clinical Trials
Narrow List by Age:
(Refer to Clinical Summary for age requirements)
Multisite
| Protocol | TAPUR |
|---|---|
| Cancer Type: | Multisite |
| Fast Facts |
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
| Protocol | EAY131 - MATCH |
|---|---|
| Cancer Type: | Molecular |
| Fast Facts |
Molecular Analysis for Therapy Choice (MATCH)
| Protocol | EAY131 - MATCH Protocol A |
|---|---|
| Cancer Type: | Molecular |
| Fast Facts |
Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol A: EAY131-A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
| Protocol | EAY131 - MATCH Protocol C2 |
|---|---|
| Cancer Type: | Molecular |
| Fast Facts |
Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol C2: EAY131-C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
| Protocol | EAY131 - MATCH Protocol K2 |
|---|---|
| Cancer Type: | Molecular |
Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol K2: EAY131-K2: Phase II Study of JNJ-42756493 (Erdafitinib) in Patients with Tumors with FGFR Mutations or Fusions.
| Protocol | EAY131 - MATCH Protocol M |
|---|---|
| Cancer Type: | Molecular |
| Fast Facts |
Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol M: EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
| Protocol | EAY131 - MATCH Protocol V |
|---|---|
| Cancer Type: | Molecular |
| Fast Facts |
Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol V: EAY131-V: Phase II Study of Sunitinib in Patients with Tumors with c-Kit Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
| Protocol | EAY131 - MATCH Protocol Z1C |
|---|---|
| Cancer Type: | Molecular |
| Fast Facts |
Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1C: EAY131-Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification
| Protocol | EAY131 - MATCH Protocol Z1G |
|---|---|
| Cancer Type: | Molecular |
Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1G: EAY131-Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
| Protocol | EAY131 - MATCH Protocol Z1K |
|---|---|
| Cancer Type: | Molecular |
| Fast Facts |
Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1K: EAY131-Z1K: Ipatasertib in Patients with Tumors with AKT Mutations
| Protocol | SWOG S1609 DART |
|---|---|
| Cancer Type: | Rare Tumors |
| Fast Facts |
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Please check out the rare protocol list to locate other studies within this disease site.
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | Alliance A221602 |
|---|---|
| Cancer Type: | Cancer Control - Nausea |
| Fast Facts |
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
| Protocol | Alliance A221701 |
|---|---|
| Cancer Type: | Cancer Control- stomatitis |
| Fast Facts |
Phase III Placebo-Controlled Trial to Evaluate Dexamethasone Use for Everolimus-Induced Oral Stomatitis: Prevention versus Early Treatment Approaches: MIST (My Individualized Stomatitis Treatment)
| Protocol | WF 10217 |
|---|---|
| Cancer Type: | Young Adult Survivors |
| Fast Facts |
Work Ability in Young Adult Survivors (WAYS)
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | Alliance A231601CD |
|---|---|
| Cancer Type: | CCDR |
| Fast Facts |
Improving Surgical Care and Outcomes in Older Cancer Patients Through Implementation of an Efficient Pre-Surgical Toolkit (OPTI-Surg)
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | DCP-001 |
|---|---|
| Cancer Type: | Multisite - Screening |
Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | EAY131 - MATCH Protocol C1 |
|---|---|
| Cancer Type: | Molecular |
| Fast Facts |
Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol C1: EAY131-C1: Crizotinib in Patients with Tumors with MET Amplification
Please check out the rare protocol list to locate other studies within this disease site.
Cancer clinical trials are research studies for developing better ways of detecting,
treating, and eventually preventing cancer. By taking part in a clinical trial,
you are among the first to receive new research treatments before they are widely
available. Your participation in a clinical trial will influence the future direction
of cancer care.
If you are interested in participating in a clinical trial, consult with your physician.
Please note: clinical trials are not risk free. Patients must explore the options
that are best for their individuals needs with the help of their physician.
